LIPA Genotype

If you or a close relative has been told you have high cholesterol, fatty liver, or a stubborn liver enzyme problem that does not improve with weight loss, there is a small chance the real cause is hiding in a single gene. The LIPA (lysosomal acid lipase A) gene contains the blueprint for an enzyme your cells use to break down stored fat and cholesterol, and inherited changes in this gene can quietly drive symptoms that look identical to common conditions.

This is a one-time genetic test. The result you get at 30 is the same one you would get at 70. What changes is how you use it: to confirm a diagnosis, to redirect treatment, and to alert family members who may carry the same variant.

What This Gene Actually Does

The LIPA gene encodes lysosomal acid lipase, an enzyme that breaks apart cholesterol esters and triglycerides inside tiny recycling compartments in your cells. When the enzyme works normally, cholesterol and fat are processed and shuttled where they need to go. When LIPA carries two damaging copies, fat accumulates inside cells, especially in the liver, spleen, and the lining of blood vessels.

Researchers have catalogued well over 100 disease-causing LIPA variants, with one large analysis identifying roughly 120 variants in total. The most common pathogenic variant worldwide is c.894G>A, which sits at the splice junction of exon 8 and causes the cell to skip that piece of the gene when assembling the enzyme. Many affected patients in international registries carry this variant on one or both copies of the gene.

The Rare but Serious Condition It Reveals

Two damaged copies of LIPA cause lysosomal acid lipase deficiency, abbreviated LAL-D. The severity depends on how much residual enzyme function remains. Infants with almost no enzyme activity develop Wolman disease, which is usually fatal in the first year without treatment. Children and adults with partial enzyme function develop cholesteryl ester storage disease (CESD), a slower-progressing form that often gets missed for years.

LAL-D is rare. Pooled analysis estimates roughly 1 case per 177,452 people, with about 1 in 421 people carrying a single pathogenic variant. Carrier frequencies vary by ancestry, and in some populations are estimated closer to 1 in 350.

Why It Often Looks Like Something Else

The reason LAL-D is so often missed is that its symptoms overlap with two extremely common conditions: familial hypercholesterolemia and nonalcoholic fatty liver disease (NAFLD). Registry and cohort data consistently show diagnostic delays of around three years from first symptoms to diagnosis, and by that point a substantial share of patients already have advanced liver scarring or cirrhosis on biopsy.

The classic picture is an enlarged liver, elevated liver enzymes (ALT and AST), high LDL cholesterol, high triglycerides, and low or normal HDL cholesterol. In one Polish series, every patient with the disease had dyslipidemia, and 79% had elevated transaminases. In a pediatric series, two children labeled as having NAFLD were eventually unmasked as having LAL-D when their liver numbers failed to improve after weight loss.

Heart Disease Risk and Common LIPA Variants

Even people who do not have the rare disease can carry common LIPA variants that subtly nudge cardiometabolic risk. Multiple intronic variants near LIPA (regions of the gene between the coding pieces) have been linked to premature coronary artery disease. In the Mexican GEA study of 1,846 participants, two LIPA polymorphisms were associated with greater odds of early heart disease, as well as with low HDL cholesterol, high triglycerides, metabolic syndrome, and type 2 diabetes.

The mechanism for the common intronic risk variants appears unusual. These risk versions are associated with higher LIPA activity in monocytes and macrophages (immune cells that infiltrate artery walls), and laboratory experiments show that boosting LIPA in these cells drives macrophage growth, programmed cell death, and inflammatory gene activity. For these intronic variants, the link to heart disease appears to run through artery wall inflammation rather than through plasma cholesterol. The picture is more complex for the coding variant rs1051338, which has been shown to reduce lysosomal LAL protein and activity, so the overall biology is not fully settled.

Fatty Liver and Metabolic Traits

A common missense LIPA variant called rs1051338 has been linked to worse fatty liver disease in a single small study. In that single-center study of 74 patients with NAFLD and dyslipidemia, those carrying the rare version of this variant had higher triglycerides, higher liver enzymes, and lower HDL cholesterol, alongside more severe steatosis. LIPA is not among the major genes identified in large genome-wide studies of NAFLD (such as PNPLA3, TM6SF2, GCKR, HSD17B13, and MBOAT7), so these findings should be treated as preliminary. In a separate study of 1,751 severely obese patients, several LIPA polymorphisms were associated with differences in blood pressure and HDL cholesterol.

When a Familial Hypercholesterolemia Diagnosis Is Wrong

Studies of patients carrying a familial hypercholesterolemia (FH) label sometimes find LIPA variants instead. In a screening of FH cohorts without LDLR, APOB, or PCSK9 mutations, four children were ultimately identified as having LAL-D. Expert panels now recommend including LIPA in the gene panel for evaluating primary hypercholesterolemia, alongside LDLR, APOB, PCSK9, LDLRAP1, ABCG5, ABCG8, and APOE.

This matters because the treatment differs. LAL-D has a specific approved therapy (sebelipase alfa, an enzyme replacement) that addresses the underlying enzyme deficiency. A patient mislabeled as having FH may spend years on statins that do not fully resolve the problem.

One-Time Result, Lifetime Use

Your LIPA genotype does not change. Whatever variants you inherited at conception are the variants you have for life, so there is no retesting cadence for the gene itself. The ongoing tracking happens downstream: if you carry biallelic pathogenic variants, regular liver enzymes, lipid panels, liver imaging, and LAL enzyme activity tests become your monitoring tools, ideally at least once a year and more often if you are on therapy.

If you carry only one pathogenic variant, you are a carrier and will not develop the disease, but each of your biological children has roughly a 50% chance of inheriting that copy. Carrier status also has implications for partners and family planning. Common LIPA polymorphisms (the kind linked to subtle heart and liver risk) do not have a single threshold and are best interpreted alongside lipid testing, hs-CRP, and liver enzymes.

When Results Can Be Misleading

Genetic testing has its own confounders that differ from blood tests of changing biomarkers.

• Panel coverage limits: the assay only detects the variants it is designed to find. A negative result does not rule out a rare LIPA variant that was not on the panel. When clinical suspicion is high but the test is negative, full LIPA sequencing may be warranted because some pathogenic variants live in intronic or regulatory regions that standard exome panels miss.
• Ethnic-specific frequencies: the c.894G>A exon 8 splice variant is most common in people of European ancestry. African and Asian populations have a different mutation spectrum, and full-gene sequencing may be needed rather than targeted SNP testing.
• Variants of uncertain significance: sequencing can return a rare change in LIPA whose effect on the enzyme is not yet known. These results require enzyme activity testing to interpret.
• Clinical-grade versus direct-to-consumer: a consumer genetic report may flag a single LIPA variant but is not validated for diagnosing LAL-D. A positive or suspicious result should always be confirmed with a clinical-grade lab and LAL enzyme activity.

What an Unexpected Result Should Prompt You to Do

If your test identifies a single pathogenic LIPA variant, you are a carrier. Carriers do not develop LAL-D, but biological siblings have a 50% chance of also being carriers, and any biological child you have with another carrier could inherit two copies. Genetic counseling is the right next step, and partners should consider testing before family planning.

If your test identifies two pathogenic variants, the next move is to confirm the diagnosis with a LAL enzyme activity test (typically from a dried blood spot) and to order a workup that includes a full lipid panel, ALT, AST, GGT, abdominal imaging, and often a fibrosis assessment. Referral to a hepatologist and a metabolic disease specialist is appropriate, and enzyme replacement therapy may be an option. If you only carry a common variant linked to heart disease or fatty liver risk, the response is to tighten your standard cardiovascular and metabolic workup: ApoB, Lp(a), hs-CRP, liver enzymes, and a baseline coronary artery calcium scan if age-appropriate.

What This Test Cannot Tell You

Carrying a single pathogenic LIPA variant does not mean you will develop disease. Carrying two variants does not predict exactly when symptoms will appear or how severe they will be. Even within the same family, the same mutation can produce earlier or later onset and different organ involvement. Common LIPA polymorphisms shift risk modestly; they do not guarantee an outcome in either direction. The value of the test comes from acting on a strong signal early, not from reading a single result as destiny.